WO2019031902A3 - (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물 - Google Patents

(r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물 Download PDF

Info

Publication number
WO2019031902A3
WO2019031902A3 PCT/KR2018/009151 KR2018009151W WO2019031902A3 WO 2019031902 A3 WO2019031902 A3 WO 2019031902A3 KR 2018009151 W KR2018009151 W KR 2018009151W WO 2019031902 A3 WO2019031902 A3 WO 2019031902A3
Authority
WO
WIPO (PCT)
Prior art keywords
methansulfonylamino
difluoro
pyridin
acrylamide
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/009151
Other languages
English (en)
French (fr)
Other versions
WO2019031902A2 (ko
Inventor
최준호
조원경
신광현
우병영
이기화
김민수
노종화
박미영
박영호
박은실
박제홍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to KR1020197035088A priority Critical patent/KR102540472B1/ko
Priority to US16/638,038 priority patent/US11957669B2/en
Priority to CN201880052207.XA priority patent/CN110996908A/zh
Priority to JP2020502201A priority patent/JP7108681B2/ja
Priority to EP18845037.3A priority patent/EP3666254B1/en
Publication of WO2019031902A2 publication Critical patent/WO2019031902A2/ko
Publication of WO2019031902A3 publication Critical patent/WO2019031902A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

(R)-N-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 제1 성분으로 포함하고, 셀룰로오스계 폴리머를 제2 성분으로 포함하는 약학 조성물에 관한 것으로, 본 발명의 조성물은 결정형성이 장기간 지연되는 제형 특성을 가진다.
PCT/KR2018/009151 2017-08-11 2018-08-10 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물 Ceased WO2019031902A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020197035088A KR102540472B1 (ko) 2017-08-11 2018-08-10 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
US16/638,038 US11957669B2 (en) 2017-08-11 2018-08-10 Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
CN201880052207.XA CN110996908A (zh) 2017-08-11 2018-08-10 包含(r)-n-[1-(3,5-二氟-4-甲磺酰氨基-苯基)-乙基]-3-(2-丙基-6-三氟甲基-吡啶-3-基)-丙烯酰胺的药物组合物
JP2020502201A JP7108681B2 (ja) 2017-08-11 2018-08-10 （ｒ）‐ｎ‐［１‐（３，５‐ジフルオロ‐４‐メタンスルホニルアミノ‐フェニル）‐エチル］‐３‐（２‐プロピル‐６‐トリフルオロメチル‐ピリジン‐３‐イル）‐アクリルアミドを含む医薬組成物
EP18845037.3A EP3666254B1 (en) 2017-08-11 2018-08-10 Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170102316 2017-08-11
KR10-2017-0102316 2017-08-11

Publications (2)

Publication Number Publication Date
WO2019031902A2 WO2019031902A2 (ko) 2019-02-14
WO2019031902A3 true WO2019031902A3 (ko) 2019-06-20

Family

ID=65271570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009151 Ceased WO2019031902A2 (ko) 2017-08-11 2018-08-10 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물

Country Status (7)

Country Link
US (1) US11957669B2 (ko)
EP (1) EP3666254B1 (ko)
JP (1) JP7108681B2 (ko)
KR (1) KR102540472B1 (ko)
CN (1) CN110996908A (ko)
TW (1) TWI805601B (ko)
WO (1) WO2019031902A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230330019A1 (en) * 2022-04-15 2023-10-19 Mark Michael MENNING Emulsion formulations of poorly water-soluble compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020097298A (ko) * 2001-06-20 2002-12-31 주식회사 엘지생활건강 사용감이 개선된 치아 미백 용 패취
JP2017031065A (ja) * 2015-07-29 2017-02-09 ポーラ化成工業株式会社 ハイドロキノン誘導体の結晶化抑制方法。

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
AU2002250058B2 (en) 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
EP1758579A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
FR2887149B1 (fr) 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
AU2005303492A1 (en) 2004-11-10 2006-05-18 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxy acetamide compounds
EP2311793A1 (en) 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US20080095720A1 (en) 2006-10-18 2008-04-24 Conopco, Inc., D/B/A Unilever Skin Benefit Compositions with a Vanilloid Receptor Antagonist
EP2099420B8 (en) 2006-11-17 2017-03-15 PharmaSol GmbH Nanocrystals for use in topical cosmetic formulations and method of production thereof
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
CA2677649A1 (en) 2007-02-09 2008-08-21 Forest Laboratories Holdings Limited Bioavailable formulations of heterocyclic compounds
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
US20120295935A1 (en) 2010-01-21 2012-11-22 Michael Frid Mixed aminal pharmaceutical compositions and uses thereof
WO2012122274A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Self-emulsifying formulations and methods of use thereof
RU2616612C2 (ru) 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
US20150004237A1 (en) * 2012-01-09 2015-01-01 Virginia Tech Intellectual Properties, Inc. Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs
AU2013328695B9 (en) 2012-10-11 2018-05-17 Nerre Therapeutics Limited Novel uses
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CA3109285A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112017014297B1 (pt) 2015-01-02 2021-11-16 Koninklijke Douwe Egberts B.V. Método para preparar um concentrado de café, e, concentrado de café
KR20160101554A (ko) 2015-02-17 2016-08-25 (주)아모레퍼시픽 N-[4-(1-아미노에틸)-페닐]-메탄술폰아미드 유도체의 카이랄 분할 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020097298A (ko) * 2001-06-20 2002-12-31 주식회사 엘지생활건강 사용감이 개선된 치아 미백 용 패취
JP2017031065A (ja) * 2015-07-29 2017-02-09 ポーラ化成工業株式会社 ハイドロキノン誘導体の結晶化抑制方法。

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARK, Y.-H.: "Oral and topical pharmacokinetic studies of a novel TRPV1 antagonist, PAC-14028 in rats and minipigs using liquid chromatography/ tandem mass spectrometric method", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSI S, vol. 61, 14 August 2012 (2012-08-14), pages 8 - 14, XP028886699 *
YUN, J.-W.: "Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models", J. INVEST. DERMATOL., 2011, pages 1576 - 1579, XP055582204, doi:10.1038/jid.2011.87 *
YUN, J.-W.: "TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery", J. DERMATOL. SCI., vol. 62, no. 1, 2011, pages 8 - 15, XP028166554 *

Also Published As

Publication number Publication date
KR20200030499A (ko) 2020-03-20
TWI805601B (zh) 2023-06-21
CN110996908A (zh) 2020-04-10
JP7108681B2 (ja) 2022-07-28
US20200215040A1 (en) 2020-07-09
WO2019031902A2 (ko) 2019-02-14
JP2020530444A (ja) 2020-10-22
US11957669B2 (en) 2024-04-16
EP3666254B1 (en) 2024-12-04
EP3666254C0 (en) 2024-12-04
EP3666254A2 (en) 2020-06-17
KR102540472B1 (ko) 2023-06-08
EP3666254A4 (en) 2020-07-29
TW201909895A (zh) 2019-03-16

Similar Documents

Publication Publication Date Title
WO2022221528A3 (en) Kras g12c inhibitors
EP4501932A3 (en) Kras g12c inhibitors
MX392863B (es) Composiciones de microcápsulas estables.
PH12022550580A1 (en) Oral product with cellulosic flavor stabilizer
WO2019125011A3 (ko) 금속-유기 골격체 및 나노셀룰로오스를 이용한 경피전달용 복합체
PH12022550469A1 (en) Kras g12d inhibitors
MX2025000350A (es) Composiciones de microcapsulas estabilizadas con agentes de control de la viscosidad
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
AU2016278853A8 (en) Petrolatum-based compositions comprising cationic biocides
MX2018006288A (es) Inhibidores de acc tipo ester y usos de los mismos.
NZ772669A (en) Wood preservative composition
EP4338752A3 (en) Stable liquid pharmaceutical preparation
WO2019120234A3 (zh) 作为溴结构域蛋白质抑制剂的化合物和组合物
EA201992504A1 (ru) Ингибиторы magl на основе пиразола
MX2021001376A (es) Carboxamidas como inhibidores de proteasa específicos de ubiquitina.
EP3694331A4 (en) INDAZOLYL-SPIRO [2,3] HEXANCARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES
SG11202110388VA (en) Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same
ZA202310843B (en) Chromene derivatives as inhibitors of tcr-nck interaction
SA517390552B1 (ar) مركبات بلورية مثبط امتصاص ثلاثي غير متوازن
EP3964512A4 (en) CASEIN KINASE INHIBITOR 1epsilon, PHARMACEUTICAL COMPOSITION AND USE THEREOF
PH12021551224A1 (en) Quaternary ammonium salts as inhibitors of trimethylamine production
PH12017501567A1 (en) Ophthalmic composition
BR112018012043A2 (pt) processo para a redução da transpiração
BR112018003617A2 (pt) adesivo não aquoso compreendendo lidocaína e método para administrar referido adesivo

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18845037

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020502201

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018845037

Country of ref document: EP

Effective date: 20200311